Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 91.90K | 46.90K | 81.20K | 122.70K | -131.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.90K | 46.90K | 81.20K | 122.70K | -131.90K |
| Cost of Revenue | 92.70K | 21.10K | 53.20K | 102.30K | 203.30K |
| Gross Profit | -800.00 | 25.80K | 28.00K | 20.50K | -335.20K |
| SG&A Expenses | 100.00 | 286.90K | 523.10K | 271.10K | 389.60K |
| Depreciation & Amortization | 11.30K | 11.30K | 11.50K | 11.30K | 10.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.10K | 319.30K | 587.90K | 384.60K | 603.60K |
| Operating Income | -12.20K | -272.40K | -506.60K | -261.90K | -735.50K |
| Income Before Tax | 1.56M | 8.98M | -298.60K | -499.40K | -1.33M |
| Income Tax Expenses | -838.70K | 1.20M | -- | -- | -- |
| Earnings from Continuing Operations | 2.40M | 7.77M | -298.60K | -499.40K | -1.33M |
| Earnings from Discontinued Operations | 206.40K | 925.30K | -- | -- | 7.85M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 75.20K |
| Net Income | 2.61M | 8.70M | -298.60K | -499.40K | 6.59M |
| EBIT | -12.20K | -272.40K | -506.60K | -261.90K | -735.50K |
| EBITDA | -900.00 | -261.10K | -495.20K | -250.60K | -724.90K |
| EPS Basic | 0.02 | 0.05 | 0.00 | 0.00 | 0.04 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | 0.02 | 0.05 | 0.00 | 0.00 | 0.04 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Average Diluted Shares Outstanding | 162.25M | 162.25M | 162.25M | 162.25M | 162.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |